Pulse Biosciences Reports Q2 2025 Earnings: Advancements in Clinical Programs and Strong Cash Position

Pulse Biosciences reported Q2 2025 progress and results, highlighting advancements in clinical programs and financial results. The company expanded its soft tissue ablation pilot program and made progress in atrial fibrillation treatment studies, including FDA applications and positive clinical outcomes in Europe. Despite a GAAP net loss of $19.2 million, Pulse Biosciences maintains a strong cash position with $106.3 million in cash and cash equivalents.

Title: Pulse Biosciences Reports Q2 2025 Progress and Results

Pulse Biosciences, Inc. (Nasdaq: PLSE) has released its Q2 2025 financial results, highlighting advancements in its clinical programs and financial performance. The company reported a GAAP net loss of $19.2 million, a significant increase from the prior year's $11.4 million, driven by increased administrative expenses and stock-based compensation [1]. Despite this, Pulse Biosciences maintains a strong cash position with $106.3 million in cash and cash equivalents as of June 30, 2025 [1].

The company has made notable progress in its clinical programs. Pulse Biosciences expanded its soft tissue ablation pilot program, treating over 140 patients with benign thyroid nodules to date across multiple centers [2]. The company has also identified five sites to participate in a post-market study of the treatment of benign thyroid disease, with plans to commence enrollment in Q3 upon receipt of IRB approvals [2].

In the atrial fibrillation (AF) treatment area, Pulse Biosciences submitted FDA IDE applications for both its cardiac surgical clamp and 360-catheter. The company has treated 40 patients to date in Europe as part of the nsPFA Cardiac Surgery System multi-center, first-in-human AF feasibility study, generating positive clinical outcomes [2]. The company remains on track to commence the IDE pivotal study for both devices in the next few months.

Pulse Biosciences is also pursuing strategic partnerships to accelerate market penetration and commercial infrastructure development. The company is in partnership discussions with market leaders in the electrophysiology space and aims to have a partnership available for its commercial timeline [2].

The company's financial and operational growth is reflected in its increased GAAP costs and expenses, which rose by $8.5 million to $20.3 million compared to the prior year period [1]. Despite this, Pulse Biosciences expects quarterly cash use to increase further as it invests in commercial infrastructure and IDE clinical studies [1].

In conclusion, Pulse Biosciences reported mixed financial results in Q2 2025, with a GAAP net loss offset by a strong cash position. The company's advancements in clinical programs and strategic partnerships position it well for future growth in the medical device market.

References:
[1] https://finance.yahoo.com/news/pulse-biosciences-inc-plse-q2-071226303.html
[2] https://www.biospace.com/press-releases/pulse-biosciences-reports-business-updates-and-second-quarter-2025-financial-results